Table 1

Eligibility criteria for network meta-analysis

PICOS elementInclusion criteriaExclusion criteria
Population

  • Adults (≥18 years);

  • Idiopathic overactive bladder, with/without urinary incontinence;

  • Conditions described as:

    • Refractory detrusor overactivity;

    • Idiopathic urge urinary incontinence;

    • Non-neurogenic urge urinary incontinence.

  • Patients with overactive bladder and urinary incontinence with a known cause (eg, surgery, pregnancy, benign prostatic hyperplasia, bladder outlet obstruction;

  • Neurogenic overactive bladder;

  • Stress urinary incontinence;

  • Bladder oversensitivity;

  • Bladder hypersensitivity;

  • Mixed populations where results not reported separately for idiopathic overactive bladder subgroup.

Intervention

  • OnabotulinumtoxinA (all doses);

  • Mirabegron (all doses).

Other variants of botulinum toxin such as Dysport (abobotulinumtoxinA).
Comparator

  • OnabotulinumtoxinA;

  • Mirabegron;

  • Sacral nerve stimulation;

  • Percutaneous tibial nerve stimulation;

  • Anticholinergics (including solifenacin/tolterone);

  • Sham treatments;

  • Placebo;

  • Best supportive care.

Other variants of botulinum toxin such as Dysport (abobotulinumtoxinA).
Outcomes

  • Episodes of urinary incontinence:

    • Change in number of episodes;

    • Proportion of patients who achieve ≥50% reduction in number of episodes

  • Urinary frequency;

  • Urgency;

  • Nocturia.

Study design

  • Randomised controlled trials;

  • Cross-over randomised controlled trials if data reported at cross-over.

  • Retrospective studies;

  • Non-English reports;

  • Abstracts/conference presentations.

  • PICOS, Population/Patients, Interventions, Comparators/Control, Outcomes, Study design.